HDAC7 and acute lymphoblastic leukemia: In conclusion, we propose that the combinatorial therapy presented here, with the ability to induce HDAC7 biomarker expression, is a promising strategy to improve the response of t(4;11) pro-B-ALL and ultimately improve overall survival.